We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Dose-Escalated Radiotherapy for Primary Tracheobronchial Adenoid Cystic Carcinoma.
- Authors
Lee, Jeong Ha; Jang, Jeong Yun; Noh, Jae Myoung; Yang, Kyungmi; Pyo, Hongryull
- Abstract
Simple Summary: The optimal radiotherapy (RT) dose for tracheobronchial adenoid cystic carcinoma (ACC) remains unclear due to its scarcity. This retrospective study evaluated the efficacy of dose-escalated RT for primary tracheobronchial ACC by dividing patients into groups of either low (<70.0 Gy EQD2) or high (≥70.0 Gy EQD2) RT doses. In the definitive RT group, the high-dose group showed better local control and survival rates compared to the low-dose group. The treatment related toxicities were the trachea or main bronchus stenosis. Dose-escalated RT may be effective for the definitive treatment of tracheobronchial ACC. Primary tracheobronchial adenoid cystic carcinoma (ACC) is a rare malignancy, so the optimal radiotherapy (RT) dose remains unestablished. We aimed to evaluate the effectiveness of dose-escalated RT for primary tracheobronchial ACC. We retrospectively reviewed 48 patients who had undergone definitive or postoperative RT. Patients classified into the low- and high-dose groups received RT doses <70.0 and ≥70.0 Gy in EQD2, respectively. The primary endpoint was freedom from local progression (FFLP) and overall survival (OS). Throughout the follow-up period, seven patients (14.6%) experienced local progression, while 31 (64.6%) exhibited distant metastasis, most commonly in the lungs. In total, the 5-year FFLP and OS rates were 85.7 and 84.7%, respectively. Multivariate analysis revealed that regional lymph node metastasis at diagnosis and receipt of definitive RT were associated with poorer OS. In the subgroup analysis, the definitive RT group had a 5-year FFLP rate of 33.3 and 78.2% in the low- and high-dose groups (p = 0.065), whereas 5-year OS rates were 66.7 and 79.0%, respectively (p = 0.022). Four patients (8.3%) experienced Grade 3 toxicity with tracheal or main bronchus stenosis. Dose-escalated RT with conventional fractionation may be effective in patients with tracheobronchial ACC, especially for a definitive aim.
- Subjects
REFERENCE values; RADIOTHERAPY; PATIENT safety; CANCER patients; RETROSPECTIVE studies; DESCRIPTIVE statistics; MULTIVARIATE analysis; ADENOID cystic carcinoma; METASTASIS; DRUG efficacy; RADIATION doses; COMPARATIVE studies; BRONCHIAL tumors; OVERALL survival
- Publication
Cancers, 2024, Vol 16, Issue 11, p2127
- ISSN
2072-6694
- Publication type
Article
- DOI
10.3390/cancers16112127